Navigation Links
Drugs Best First Defense Against Heart Disease for Diabetics
Date:6/7/2009

ot answer" the question of whether all diabetic patients with multi-vessel coronary artery disease might be better treated with optimal drug therapy plus angioplasty or bypass.

Results from another ongoing trial "may shed more light" on the issue, the statement added.

What the study did show was that for people with diabetes and stable coronary artery disease, "a strategy of prompt revascularization [surgical opening of arteries] did not benefit patients relative to medical therapy alone," said trial leader Maria Mori Brooks, associate professor of epidemiology at the University of Pittsburgh Graduate School of Public Health.

Increasing severity of disease seemed to matter, however. "For patients who had more severe heart disease, there was a benefit from bypass surgery vs. medical therapy alone," she said.

That benefit was not seen in survival rates, which did not differ much in groups given various treatments. The real gap in outcomes came in the rate at which patients suffered major cardiovascular events such as heart attack and stroke. Those were significantly lower when bypass surgery was added to drug therapy, the researchers found.

The results confirm those of a similar trial reported two years ago, noted Dr. William Boden, a professor of medicine and preventive medicine at the State University of New York, and co-author of an editorial accompanying the journal report. In particular, the new study showed that if a procedure is needed to restore coronary blood flow, "bypass surgery is more likely than angioplasty to reduce the incidence of recurrent heart attacks. No other study to my knowledge has shown that bypass surgery reduces the incidence of myocardial infarction [heart attack]," he said.

Yet dissent arose even on that point.

Dr. Kirk Garratt, director of interventional cardiovascular research at Lenox Hill Hospital in New York City, said that the new trial did not dir
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved  

1

GOOD

Page: 1 2 3

Related medicine news :

1. New review suggests caution on drugs to raise good cholesterol
2. Can cancer drugs combine forces?
3. Study provides hope that some transplant patients could live free of antirejection drugs
4. Study provides hope that some transplant patients could live free of anti-rejection drugs
5. RA Drugs Linked to Slight Skin Cancer Risk
6. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
7. Rock N Roll: Sex, Drugs and an Early Exit
8. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
9. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
10. Are Bargaining Groups Hired by Independent Drugstores Causing Payment Delays to Pharmacies?
11. 2 drugs equally effective for heart patients undergoing angioplasty, Mayo study finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drugs Best First Defense Against Heart Disease for Diabetics
Drugs Best First Defense Against Heart Disease for Diabetics
(Date:12/15/2009)... Synthetic Fillers and Large Volume Injections Dangerous , ... ... -- The popularity and hype surrounding buttock augmentation and other ... outside U.S. borders is an alarming and potentially deadly trend, ... Permanent fillers such as polymethylmethacrylate (PMMA), silicone, and polyacrylimide used ...
(Date:12/15/2009)... Seattle, WA) – Delicious Planet, Seattle’s premier organic meal delivery ... launch of its Delicious Planet Detox Program, Randi Carter, company ... ... (December 15, 2009 – Seattle, WA) – Delicious ... is accepting orders now for the launch of its Delicious ...
(Date:12/15/2009)... HONG KONG, Dec. 15 /PRNewswire-Asia/ --, Key points:, ... Cells (South) Company, Limited with ... exclusive access to about 1 million new births, ... -- CordLife,s geographical footprint in Asia Pacific is enlarged, with, ... India, two of the largest and fastest, ...
(Date:12/15/2009)... out-of-pocket costs for beneficiaries based on health status categories and ... ... Antonio, TX (Vocus) Dec. 14, 2009 -- Physicians Health Choice ... recognized for cost-sharing effectiveness and value in the design of ... Medicare beneficiaries. The Medicare Advantage company won for its ...
(Date:12/15/2009)... , ... (PRWEB) December 10, 2009 -- Millions of men and women suffer ... clusters of red, blue or purple veins that spider-web across the nose, ... US, it’s been estimated that 25-30% of women and 10-20% of men ... Veinwave has been available for over 8 years in Europe ...
Breaking Medicine News(10 mins):Health News:Physicians Coalition for Injectable Safety Warns Buttock-Boosting Injections Risky and Deadly 2Health News:Physicians Coalition for Injectable Safety Warns Buttock-Boosting Injections Risky and Deadly 3Health News:Physicians Coalition for Injectable Safety Warns Buttock-Boosting Injections Risky and Deadly 4Health News:Delicious Planet Organic Meal Service Is Accepting Orders For Its Weekly Detox Program Delivery 2Health News:Delicious Planet Organic Meal Service Is Accepting Orders For Its Weekly Detox Program Delivery 3Health News:Delicious Planet Organic Meal Service Is Accepting Orders For Its Weekly Detox Program Delivery 4Health News:CordLife Secures Strategic Presence in China 2Health News:CordLife Secures Strategic Presence in China 3Health News:Physicians Health Choice Receives Senior Choice Gold Award for 2010 Medicare Plan Benefits 2Health News:Physicians Health Choice Receives Senior Choice Gold Award for 2010 Medicare Plan Benefits 3Health News:Physicians Health Choice Receives Senior Choice Gold Award for 2010 Medicare Plan Benefits 4Health News:Vein Center & CosMed, Inc. Selected as Exclusive St. Louis Provider of FDA-Cleared Device 2
... Nov. 26 The Providence Service,Corporation (Nasdaq: PRSC ... its financial advisor. , ... considering strategic,options relating to, among other things, delevering its debt, ... UBS,Investment Bank has been retained in connection with selling ...
... these products, experts say , , WEDNESDAY, Nov. 26 (HealthDay ... while at work may be more likely to have ... new report says. , Many cosmetics such as ... called phthalates, such as diethyl phthalate (DEP) and dibutyl ...
... Children whose eyes are misaligned and point outward ... illness by early adulthood, according to findings of ... Pediatrics ( http://pediatrics.aappublications.org/cgi/content/full/122/5/1033 ), the official ... The retrospective study examined the medical records of ...
... rural women, it,s cheaper and less time-consuming than ... News) -- Telephone counseling may be as effective as ... report. , The University of Florida study included 234 ... areas of northern Florida. , All the women completed ...
... engagement practitioners from across the world are to share ... held in South Africa, organised by the Wellcome Trust. ... to empower" will take place from 2-5 December ... KwaZulu-Natal. It will bring together practitioners working in the ...
... See Billion Dollar Increase in Value of Family Members Taking Care ... CHICAGO,Nov. 26 With the economy continuing it,s downward turn, ... ones in need. A new AARP report found the value ... than a $1 billion increase since 2006. While nearly 1.5 ...
Other Medicine News:Health News:Providence Service Corporation Retains UBS Investment Bank as its Financial Advisor in Connection With the Sale of Certain Non-Strategic Assets 2Health News:Over-the-Phone Weight Loss Counseling Works 2Health News:International workshop aims to boost public engagement work in developing countries 2Health News:International workshop aims to boost public engagement work in developing countries 3Health News:AARP Finds Value of Unpaid Family Caregiving in Illinois Hits $17 Billion 2
(Date:12/14/2009)... and sometimes uncomfortable colonoscopies may soon be a thing ... of a new screening test that is making its ... EDP Biotech Corporation (EDP) is pursuing a ... doctors can use to screen for colon cancer with ... 30% of colon cancer deaths are avoidable by early ...
(Date:12/14/2009)... Seven leading cancer physicians ... Oncology Research participated in studies ... 2009 San Antonio Breast Cancer ... the Henry B. Gonzalez Convention ... . Fifteen others presented their ...
(Date:12/14/2009)... Calif., Dec. 14 Alexza Pharmaceuticals, Inc. (Nasdaq: ... its New Drug Application (NDA) for Staccato® loxapine (AZ-004) ... AZ-004 is an inhalation product candidate being developed for ... or bipolar disorder. The IND for Staccato ... 2005. ,, "AZ-004 has delivered a predictable and consistent ...
Breaking Medicine Technology:EDP Biotech Takes Next Step in the Development of ColoMarker 2EDP Biotech Takes Next Step in the Development of ColoMarker 3US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 2US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 3US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 4US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 5US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 6US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 7US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 8US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 9Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 2Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 3Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 4Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 5Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 6Dr Alan F Dowling Named AHIMAs Next Chief Executive Officer 62460 1Dr Alan F Dowling Named AHIMAs Next Chief Executive Officer 62460 2Ministerial Roundtable Discusses Future of Medical Tourism 62455 1Ministerial Roundtable Discusses Future of Medical Tourism 62455 2Ministerial Roundtable Discusses Future of Medical Tourism 62455 3Oncolytics Biotech 28R 29 Inc Announces Exercise of Underwriters Over Allotment Option 15047 1Oncolytics Biotech 28R 29 Inc Announces Exercise of Underwriters Over Allotment Option 15047 2Oncolytics Biotech 28R 29 Inc Announces Exercise of Underwriters Over Allotment Option 15047 3Oncolytics Biotech 28R 29 Inc Announces Exercise of Underwriters Over Allotment Option 15047 4
... Cadence Pharmaceuticals,Inc. (Nasdaq: CADX ), a ... product candidates principally,for use in the hospital setting, ... nine months ended September 30, 2008., The ... development,programs for its two Phase III product candidates ...
... November 6 Bavarian,Nordic has completed a clinical safety ... HIV infected subjects that confirms the excellent,safety profile of ... this study will be submitted to the FDA and ... the RFP-3 contract. The clinical safety,report constitutes a major ...
Other Medicine Technology:Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update 2Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update 3Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update 4Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update 5Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update 6Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update 7Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update 8Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R) 2
... OcularProtect is a scientifically ... support for visual and full ... 40 key nutrients, including a ... as FloraGLO lutein, lycopene and ...
... Most people take their eyes ... your body, your eyes need proper ... eye health and vision as you ... nutrition is critical to maintaining and ...
Easy-to-use desktop QC data management solution...
Non-Temperature Ablation Catheters...
Medicine Products: